Omid Shah

Assistant Professor

Omid Shah is an Assistant Clinical Professor of Medicine at the University of California, San Francisco (UCSF). He cares for patients on the inpatient medicine direct care and teaching services at Moffit-Long Hospital and St Mary's Medical Center, San Francisco. In addition, he provides inpatient medicine consultation services at UCSF's Mission Bay Hospital.

Dr. Shah's clinical experiences span just over a decade and two continents having trained and practiced in the UK before moving to the US to complete his training in internal medicine at Columbia University Vagelos College of Physicians and Surgeons affiliate program at Mary Imogene Bassett Hospital in Cooperstown, NY.

Dr Shah is committed to contributing meaningfully to the field of hospital medicine by applying both his clinical experiences and his academic skills gained from the 3 years he spent as a clinical translational research associate at Stanford to his academic interests: quality improvement, medical education and diversity, equity and inclusion.
Education
Chief Resident, 06/2021 - Internal Medicine, Mary Imogene Bassett Hospital (Columbia School of Physicians & Surgeons Affiliate)
Residency, 06/2021 - Internal Medicine, Mary Imogene Bassett Hospital (Columbia School of Physicians & Surgeons Affiliate)
Clinical Translational Research Associate, 06/2018 - Immunology/BMT, Stanford School of Medicine
Specialty Training, 11/2014 - Neurosurgery, University Hospitals Birmingham
House Officer, 08/2011 - Medicine and Surgery, Sheffield Teaching Hospitals
MD, 06/2009 - , University of Sheffield
Honors and Awards
  • SOAMS Scholarship (Sheffield Outreach and Access to Medical Scheme), University of Sheffield, 2004
Publications
  1. Thangjui S, Shah O, Zoltick J. Is this heart failure? "Are Telehealth Visits Feasible for Vulnerable Patients?" 2022. PMID: 35321924


  2. Shah O, Tamaresis JS, Kenyon LJ, Xu L, Zheng P, Gupta P, Rangarajan K, Lee S, Spellman S, Nikiforow S, Zehnder J, Meyer EH. Analysis of the Whole CDR3 T Cell Receptor Repertoire after Hematopoietic Stem Cell Transplantation in 2 Clinical Cohorts. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2020. PMID: 32081787


  3. Xu L, Durruthy-Durruthy R, Eastburn DJ, Pellegrino M, Shah O, Meyer E, Zehnder J. Clonal Evolution and Changes in Two AML Patients Detected with A Novel Single-Cell DNA Sequencing Platform. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31366893


  4. Abid H, Watthanasuntorn K, Shah O, Gnanajothy R. Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 31245230


  5. Narayan R, Benjamin JE, Shah O, Tian L, Tate K, Armstrong R, Xie BJ, Lowsky R, Laport G, Negrin RS, Meyer EH. Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2019. PMID: 30951840


  6. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 29634689


  7. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2018. PMID: 29431743


  8. Baird JR, Monjazeb AM, Shah O, McGee H, Murphy WJ, Crittenden MR, Gough MJ. Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. "Are Telehealth Visits Feasible for Vulnerable Patients?" 2017. PMID: 28871985


  9. Tsermoulas G, Shah O, Wijesinghe HE, Silva AHD, Ramalingam SK, Belli A. Surgery for Acute Subdural Hematoma: Replace or Remove the Bone Flap? "Are Telehealth Visits Feasible for Vulnerable Patients?" 2015. PMID: 26523763